Gortec-reach trial
WebMar 5, 2024 · The GORTEC 2008-03 TPEx phase 2 study evaluating four cycles of docetaxel in combination with cisplatin and cetuximab followed by cetuximab maintenance every 2 weeks (the TPEx regimen) showed … WebMar 5, 2024 · Initially, the trial was designed with 80% power (that required 295 deaths and 416 patients), which was increased to 88% in December, 2016, because the rate of enrolment was high so a power increase was authorised …
Gortec-reach trial
Did you know?
WebGORTEC with a funding from MERCK Serono. This research was financially supported by Merck Serono S.A.S., Lyon, France, an affiliate of Merck KGaA, as part of an alliance … http://www.china-oncology.com/EN/abstract/abstract1829.shtml
WebBackground and purpose: Radiotherapy (RT) with cetuximab is an alternative for advanced-stage head and neck squamous cell carcinoma (HNSCC) patients who are unfit for cisplatin treatment. As 5-year overall survival is below 50%, it is of interest to test PD-L1 immune checkpoint blockade (avelumab) with cetuximab-RT in the curative setting. WebSep 30, 2024 · First he discusses the results of the GORTEC-REACH trial in locally advanced SCCHN testing avelumab-cetuximab-radiotherapy, and the KEYNOTE-122 study in recurrent or metastatic nasopharyngeal carcinoma testing pembrolizumab.
WebDec 1, 2024 · The GORTEC-REACH trial also enrolled 275 cisplatinineligible patients and randomized them to standard treatment with cetuximab and RT vs. the standard treatment plus avelumab. The 2-year … WebSep 23, 2024 · In the avelumab study, known as GORTEC-REACH, results in cisplatin-eligible patients were consistent with those of the previously reported JAVELIN trial with …
WebDec 1, 2024 · Several randomized phase III trials are ongoing evaluating the combination of PD-1/PD-L1 inhibitors (pembrolizumab, avelumab, etc.) with RT/CRT in LA-SCCHN, and …
WebSep 22, 2024 · This trial randomised patients to actually four arms, one was the standard of care which is ADT plus docetaxel, since docetaxel was established here, or standard of care plus abiraterone and a standard of care plus radiation versus standard of care plus abiraterone plus radiation. geforce 920m驱动425.31WebMay 17, 2024 · Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head … geforce920驱动WebApr 8, 2024 · The phase III trial JUPITER-02 randomized 289 patients 1:1 to gemcitabine and cisplatin (GC) with either toripalimab, a humanized IgG4K monoclonal PD-1 antibody, ... These include KEYNOTE-412, GORTEC-REACH, GORTEC 2015-01, NRG HN004 (Clin-icalTrials.gov identi fi er: NCT03258554) ... dcg tbsgeforce920m驱动下载WebSep 18, 2024 · Both interventions will be delivered by parents at home with monthly home visits and interim telecommunication support by study therapists. Assessments will be conducted at study entry; at 6, 12 months ca immediately postintervention (primary outcome) and 24 months ca (retention). The primary outcome will be the Mini-Assisting … d c g sweet home alabamaWebIn the phase Ib KEYNOTE-028 trial, pembro showed antitumor activity and manageable safety in a cohort of 27 patients (pts) with R/M NPC. KEYNOTE-122 (NCT02611960) is a multicenter, open-label, randomized phase III study to evaluate the efficacy and safety of pembro monotherapy vs chemo in pts with platinum-pretreated, R/M NPC. Methods dcgtrd02604p.intraservice.corp/session-listWeb16 Gortec, GORTEC-CHU Bretonneau, 37044 - Tours cedex/FR; 17 Medical Oncology Department, Centre Anticancer Antoine Lacassagne, 06189 - Nice/FR; ... In this phase II randomized trial, patients with non operated stage III-IVa-b SCC of oral cavity, oropharynx, hypopharynx and larynx and unfit for receiving high dose of cisplatin were enrolled. ... geforce 9300m gs driver download